Search
Silence Therapeutics PLC
SLNAdd to Watchlist
6.950USD
+0.190+2.81%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
327.34MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Silence Therapeutics PLC is 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 75.00 and a low of 4.00.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
34.750
Target Price
+396.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Silence Therapeutics PLC
SLN
6
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Silence Therapeutics PLC's price target?
Analysts forecast that Silence Therapeutics PLC's price target is USD 30.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 4.00.
What is the analyst rating for Silence Therapeutics PLC?
Based on the ratings of Silence Therapeutics PLC's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
